Guthriemcdonald7232
MicroRNA (miRNA) molecules, which are effective in the formation and progression of many different diseases, are 18-22 nucleotides in length and make up a type of non-coding RNA. Predicting disease-related microRNAs is crucial for understanding the pathogenesis of disease and for diagnosis, treatment, and prevention of diseases. Many computational techniques have been studied and developed, as the experimental techniques used to find novel miRNA-disease associations in biology are costly. In this paper, a Kernelized Bayesian Matrix Factorization (KBMF) technique was suggested to predict new relations among miRNAs and diseases with several information such as miRNA functional similarity, disease semantic similarity, and known relations among miRNAs and diseases. AUC value of 0.9450 was obtained by implementing fivefold cross-validation for KBMF technique. We also carried out three kinds of case studies (breast, lung, and colon neoplasms) to prove the performance of KBMF technique, and the predictive reliability of this method was confirmed by the results. Thus, KBMF technique can be used as a reliable computational model to infer possible miRNA-disease associations.
The prognostic value of treatment response in patients with non-small cell lung cancer (NSCLC) treated with immune-checkpoint inhibitors (ICIs) shown by
F-fludeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) results obtained with multiple types of PET scanners using standardized uptake value (SUV) harmonization was evaluated.
Fifty-eight patients treated with ICIs who underwent
F-FDG PET/CT examinations with nine types of PET scanners at six hospitals were enrolled. SUV harmonization of multiple PET scanner results was performed using the dedicated software packages "RAVAT" and "RC Tool for Harmonization". Tumor response was assessed by change in sum of harmonized SUVmax, according to the European Organization for Research and Treatment of Cancer (EORTC5) or the SUV of up to five lesions normalized to lean body mass, according to the PET Response Criteria in Solid Tumors (PERCIST5) and immunotherapy-modified PERCIST (imPERCIST5) criteria. The correlation between tumor respona was associated with OS. PET response criteria using harmonized metabolic parameters may be difficult to routinely employ in daily practice due to overlapping SMD and PMD, although may have a supporting role for determining prognosis.
Dyslipidemia is a very common medical disorder affecting nearly 33.5% of US adults over 20years of age. It represents the major risk factor for non-alcoholic fatty liver (NAFLD) and cardiovascular diseases, which is the most common cause of death worldwide. Elafibranor is a peroxisome proliferator-activated receptor (PPAR) alpha and delta dual agonist. A novel dual peroxisome proliferator-activated receptor alpha/delta (PPAR-α/δ), elafibranor, the agonist is an emerging therapy with promising hepatoprotective results.
To estimate the efficacy of elafibranor in patients with liver abnormalities especially non-alcoholic steatohepatitis (NASH).
We searched the following databases PubMed, SCOPUS, Web of Science, and Cochrane Library for relevant clinical trials assessing the use of silymarin in patients with NAFLD. Risk of bias assessment was performed using Cochrane's risk of bias tool. We included the following outcomes alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), HOMA-IR, total cholesterol (TC), triglyceride (TG), HDL-cholesterol (HDL-C), and LDL-cholesterol (LDL-C).
We included four clinical trials. We found that elafibranor significantly reduced the levels of ALT MD = -4.60 [-8.17, -1.04], (P = 0.01), GGT MD = -16.57 [-26.59, -6.56], (P < 0.01), TC MD = -0.37 [-0.66, -0.08], (P = 0.01), TG MD = -0.37 [-0.51, -0.24], (P < 0.01), ALP (MD = -14.45 [-18.99, -9.91], (P < 0.01), and LDL MD = -0.20 [-0.33, -0.07], (P = 0.003). There was no significant difference regarding HOMA-IR MD = -0.32 [-0.88, 0.24], (P = 0.26) and AST (P = 0.53).
PPAR-alpha/delta dual agonist, elafibranor, is a promising drug that improves most metabolic parameters in dyslipidemic patients.
PPAR-alpha/delta dual agonist, elafibranor, is a promising drug that improves most metabolic parameters in dyslipidemic patients.
Vestibular migraine (VM) commonly causes episodic vertigo/dizziness; however, its clinical features are unknown. Based on the evidence that central sensitization is related to VM pathogenesis, we hypothesized that cutaneous allodynia is frequently associated with patients with VM compared with patients without VM. This study aims to (1) elucidate the clinical features of patients with VM and (2) evaluate whether patients with VM were more frequently associated with cutaneous allodynia than patients without VM.
This cross-sectional study enrolled consecutive patients with migraine aged 18-65years. The comprehensive interview form included diagnostic questions regarding migraine and VM, demographic characteristics, migraine-specific variables, migraine-associated symptoms, and cutaneous allodynia.
A total of 245 consecutive patients with migraine (mean age = 39.5years, 81.2% women) were enrolled; 65 (26.5%) patients with VM were assigned to the VM group, 74 (30.2%) with migraine with vestibular symptoms npathogenesis. Widespread allodynia may be a useful diagnostic aid for VM.BACKGROUND AND OBJECTIVE Gentamicin is commonly used in neonates, and it requires drug concentration monitoring. The objective of this study was to determine the extent of high trough (≥ 2 mg/l) and therapeutic peak serum gentamicin concentrations (5-12 mg/l) using our current gentamicin regimen and to adjust the dosing regimen accordingly and reassess.
This was a prospective cohort study of neonates, with normal renal function, who were prescribed gentamicin. Group 1 March 2014-July 2017-gentamicin intravenous (IV) 2.5 mg/kg given every 36 h if < 30 weeks gestational age (GA) and every 24 h if ≥ 30 weeks GA; Group 2 August 2019-February 2020-gentamicin IV 3.5 mg/kg given every 36 h if < 30 weeks GA and every 24 h if ≥ 30 weeks GA. We assessed the number of neonates with aberrant trough and peak serum gentamicin concentrations.
Forty-eight neonates < 30 weeks GA and 34 ≥ 30 weeks GA were given 2.5 mg/kg gentamicin. Eleven (23%) neonates < 30 weeks GA and four (13%) ≥ 30 weeks GA had subtherapeuieved therapeutic peak concentrations in 98% and non-toxic trough concentrations in 86% of all neonates (prior to dose interval adjustment).
Obesity is a common disease among children, often accompanied by a lot of metabolic disease. Non-alcoholic fatty liver disease (NAFLD) is one of the most common complications of obesity among children and adolescents. Asprosin has been identified as a new adipokine that is closely associated with hepatic glucose metabolism. However, few data on asprosin in obese children with NAFLD are available. The present study focuses on the relationship between serum asprosin level and NAFLD in children with obesity.
A total of 110 subjects (71 boys and 39 girls aged 6-18years) were recruited from the Second Affiliated Hospital of Xi'an Jiaotong University 36 obese children with NAFLD, 39 obese children without NAFLD and 35 lean controls. Anthropometric parameters and biochemical data were measured, and the concentrations of asprosin were detected by ELISA.
The levels of serum asprosin were significantly higher in obese children, particularly those with NAFLD and were positively correlated with body mass index, waist to height ratio, fasting blood glucose, alanine aminotransferase and tumor necrosis factor-alpha. Furthermore, asprosin was independently associated with NAFLD in binary logistic regression analysis.
Serum asprosin levels were elevated in obese children, especially in those with NAFLD, and were involved in the pathogenesis of NAFLD in children with obesity.
Serum asprosin levels were elevated in obese children, especially in those with NAFLD, and were involved in the pathogenesis of NAFLD in children with obesity.
The Ontario government implemented a regulatory change to mandate the collection of socio-demographic (SD) data for individuals who tested positive for COVID-19. This change was informed by evidence of COVID-19's disproportionate impact on marginalized communities and calls for broader collection of SD data. Given the scarcity of similar efforts, there is a significant knowledge gap around implementing standardized SD data collection in public health settings.
Public Health Ontario provided collaborative support for the implementation of SD data collection, grounded in health equity principles, evidence, and best practices. We supported the addition of SD fields in Ontario's COVID-19 data collection systems, issued data entry guidance, hosted webinars for training and learning exchange, and published a resource to support the data collection process. The current focus is on building sustainability and quality improvement through continued engagement of public health units.
By November 28, 2020, almost 80% of COVID-19 cases had information recorded for at least one SD question (individual questions, range 46.8-67.0%). We hosted three webinars for the field, and the data collection resource was viewed almost 650 times. Practitioners continue to express needs for support on applying equity principles to data analysis and interpretation, and community engagement on data collection and use.
Sharing knowledge on responsive implementation supports in collaboration with the field and using current evidence and guidance will strengthen public health practice for SD data collection. Laying this groundwork will also improve the likelihood of success and sustainability of these equity-focused efforts.
Sharing knowledge on responsive implementation supports in collaboration with the field and using current evidence and guidance will strengthen public health practice for SD data collection. Laying this groundwork will also improve the likelihood of success and sustainability of these equity-focused efforts.
Tumor metastasis is the main cause of death from breast cancer patients and cell migration plays a critical role in cancer metastasis. Recent studies have shown long non-coding RNAs (lncRNAs) play an essential role in the initiation and progression of cancer. In the present study, the role of an LncRNA, Rho GTPase Activating Protein 5- Antisense 1 (ARHGAP5-AS1) in breast cancer was investigated.
RNA sequencing was performed to find out dysregulated LncRNAs in MDA-MB-231-LM2 cells. Transwell migration assays and F-actin staining were utilized to estimate cell migration ability. Selleckchem MLN7243 RNA pulldown assays and RNA immunoprecipitation were used to prove the interaction between ARHGAP5-AS1 and SMAD7. Western blot and immunofluorescence imaging were used to examine the protein levels. Dual luciferase reporter assays were performed to evaluate the activation of TGF-β signaling.
We analyzed the RNA-seq data of MDA-MB-231 and its highly metastatic derivative MDA-MB-231-LM2 cell lines (referred to as LM2) and identified a novel lncRNA (NR_027263) named as ARHGAP5-AS1, which expression was significantly downregulated in LM2 cells.
